• 1. Tri- and tetrafluoropropionamides derived from chiral secondary amines – synthesis and the conformational studies
  Monika Bilska-Markowska,Magdalena Rapp,Tomasz Siod?a,Andrzej Katrusiak,Marcin Hoffmann,Henryk Koroniak New J. Chem. 2014 38 3819
• 2. Zebra reaction or the recipe for the synthesis of heterodimeric zinc complexes
  D. J?drzkiewicz,J. Ejfler,?. John,S. Szafert Dalton Trans. 2016 45 2829
• 3. Mechanistic investigation of electrocatalytic reductive amination at copper electrode
  Taemin Kim,Dong Il Park,Sojin Kim,Dibya Yadav,Sugyeong Hong,Sun Hee Kim,Hyo Jae Yoon,Kyoungsuk Jin Chem. Commun. 2023 59 4818
• 4. Secondary amines as coupling partners in direct catalytic asymmetric reductive amination
  Zitong Wu,Shaozhi Du,Guorui Gao,Wenkun Yang,Xiongyu Yang,Haizhou Huang,Mingxin Chang Chem. Sci. 2019 10 4509
• 5. The conformations of new CF3 and CF3-CHF containing amides derived from carbohydrates: NMR, crystallographic and DFT study
  M. Bilska-Markowska,T. Siodla,E. Patyk-Ka?mierczak,A. Katrusiak,H. Koroniak New J. Chem. 2017 41 12631

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Recent Advances in the Study of Methyl(1-phenylethyl)amine (CAS: 32512-24-6) in Chemical Biology and Pharmaceutical Research

Methyl(1-phenylethyl)amine (CAS: 32512-24-6) is a chiral amine compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, also known as α-methylbenzylamine, serves as a crucial building block in the synthesis of various bioactive molecules, including pharmaceuticals, agrochemicals, and chiral auxiliaries. The renewed interest in this molecule stems from its potential role in asymmetric synthesis and its utility in the development of novel therapeutic agents.

Recent studies have focused on optimizing the synthetic routes for methyl(1-phenylethyl)amine to improve yield and enantiomeric purity. A 2023 publication in the Journal of Organic Chemistry demonstrated an efficient enzymatic resolution method using lipase-catalyzed acylation, achieving >99% enantiomeric excess (ee) for both enantiomers. This advancement addresses previous challenges in obtaining optically pure forms of the compound, which is critical for pharmaceutical applications where stereochemistry significantly impacts biological activity.

In pharmaceutical research, methyl(1-phenylethyl)amine has shown promise as a precursor in the synthesis of CNS-active compounds. A 2024 study published in Bioorganic & Medicinal Chemistry Letters reported its incorporation into novel dopamine receptor modulators with improved blood-brain barrier permeability. The structural flexibility of this amine allows for diverse modifications while maintaining favorable pharmacokinetic properties, making it particularly valuable in neuropharmacology drug discovery.

The compound's mechanism of action in biological systems has also been elucidated through recent structural biology studies. Cryo-EM analysis published in Nature Chemical Biology (2023) revealed how methyl(1-phenylethyl)amine derivatives interact with G-protein coupled receptors (GPCRs), providing atomic-level insights that are guiding the design of more selective therapeutics. These findings have opened new avenues for developing targeted treatments for neurological disorders with reduced side effects.

From a safety and toxicology perspective, recent toxicokinetic studies (Regulatory Toxicology and Pharmacology, 2024) have established comprehensive profiles for methyl(1-phenylethyl)amine and its derivatives. These studies confirm favorable safety margins at therapeutic doses while identifying specific metabolic pathways that could be optimized to enhance drug efficacy. Such data are crucial for advancing promising compounds through preclinical development stages.

Looking forward, the unique properties of methyl(1-phenylethyl)amine continue to inspire innovative applications. Current research directions include its use in PROTAC (proteolysis targeting chimera) technology for targeted protein degradation and as a component in supramolecular drug delivery systems. The compound's versatility and well-characterized chemistry position it as a valuable tool in addressing emerging challenges in drug discovery and chemical biology.

• 19131-99-8((S)-(-)-N-Methyl-1-phenylethylamine)
• 10137-87-8(N-Ethyl-1-phenylethanamine)
• 2449-49-2(N,N,α-trimethylbenzylamine)
• 18979-53-8(4-Amyloxyphenol)
• 14683-47-7(N-Methyl-1,1-diphenylmethanamine)
• 19302-16-0(N-(1-Phenylethyl)propan-2-amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)